Acceleron (XLRN) option implied volatility flat into Phase III Believe results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Acceleron Pharma (XLRN) Granted FDA Orphan Drug Designation for ACE-083 in Facioscapulohumeral Muscular Dystrophy
July 12, 2018 7:10 AM EDTAcceleron Pharma Inc. (NASDAQ: XLRN) today announced that the United States Food and Drug Administration (FDA) has granted orphan drug designation for ACE-083, the Companys locally acting Myostatin+ muscle agent, for the treatment of patients with facioscapulohumeral muscular dystrophy (FSHD).
We are pleased to receive orphan drug designation for ACE-083, which has shown the potential to address an area of high unmet medical need, said Robert K. Zeldin, M.D., Chief Medical Officer of Acceleron. We believe that ACE-083 could become an important new treatment for patients with FSHD whose muscle weakness negatively affects their... More
Acceleron Pharma (XLRN) PT Raised to $62 at UBS
July 10, 2018 8:01 AM EDTUBS raised its price target on Acceleron Pharma (NASDAQ: XLRN) to $62.00 (from $57.00) while maintaining a Buy rating.
... MoreAcceleron Pharma (XLRN) PT Raised to $74 at H.C. Wainwright Following Positive BELIEVE Results
July 10, 2018 7:34 AM EDTH.C. Wainwright raised its price target on Acceleron Pharma (NASDAQ: XLRN) to $74.00 (from $69.00) while maintaining a Buy rating following the company's announcement, along with Celgene (NASDAQ: CELG), of positive results from the Phase 3 BELIEVE study of luspatercept in... More
